Combined regimens based on immune checkpoint inhibitors (anti-PD1 or anti-CTLA4) and modified T-cell therapies are currently being tested in specific sarcoma subtypes with a significant clinical benefit for the patients (Pollack et al., 2018; Dyson et al., 2019; Heymann et al., 2020). This evidence concerns the gene PDCD1 and sarcoma.